CVS Health on Wednesday reported first-quarter revenue and adjusted earnings that missed expectations and slashed its full-year profit outlook, citing higher medical costs that are dogging the U.S. insurance industry.Shares of the company dropped 10% in premarket trading.The drugstore chain expects 2024 adjusted earnings of at least $7 per share, down from a previous guidance of at least $8.30 per share. Analysts surveyed by LSEG were expecting full-year adjusted profit of $8.28 per share. CVS also cut its ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to_________ Commission File Number: 001-01011 CVS HEALTH CORPORATION (Exact name of registrant as specified in its charter) Delaware 05-0494040 (Sta ...

Exhibit 99.1 CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE First Quarter Highlights • Total revenues increased to $88.4 billion, up 3.7% compared to prior year • GAAP diluted EPS of $0.88 and Adjusted EPS of $1.31 • Generated cash flow from operations of $4.9 billion 2024 Full-Year Guidance • Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06 • Revised Adjusted EPS guidance to at least $7.00 from at least $8.30 • Revised cash flow from ope ...

First Quarter Highlights Total revenues increased to $88.4 billion, up 3.7% compared to prior year GAAP diluted EPS of $0.88 and Adjusted EPS of $1.31 Generated cash flow from operations of $4.9 billion 2024 Full-Year Guidance Revised GAAP diluted EPS guidance to at least $5.64 from at least $7.06 Revised Adjusted EPS guidance to at least $7.00 from at least $8.30 Revised cash flow from operations guidance to at least $10.5 billion from at least $12.0 billion CEO Commentary"The current environment does not ...

Key PointsCVS Stock trades near a 52-week low, allowing investors to build a potential bull case. Compared to its closest competitor, Walgreens, CVS still holds more market share, and markets reward this. Financials back analysts' EPS projections and price targets to give investors the upside they could be hunting for.5 stocks we like better than UBS GroupAfter underperforming its peers in the healthcare sector, shares of CVS Health Co. NYSE: CVS are now nearing a 52-week low price. Underperforming the Heal ...

NEW YORK - NY - MARCH 01: People visit the CVS pharmacy store at Times Square on March 1, 2024 in ... [+] New York City. (Photo by Eduardo Munoz Alvarez/VIEWpress via Getty Images)Corbis via Getty ImagesCVS Health (NYSE: CVS) will report its Q1 2024 results on Wednesday, May 1. We expect the company’s revenues to come in at $90 billion, slightly above the consensus estimate of $89.2 billion. This would mark year-over-year growth of 5.5%. Earnings will likely come in at about $1.74 on a per-share and adjuste ...

The company has one major strength: It offers essential services.Dividend stocks are often in high demand due to the passive income they provide and their ability to deliver superior returns over long periods. So finding excellent income stocks to buy on the dip is a dream come true for many investors -- but only if the company in question has what it takes to rebound.Is that the case for CVS Health (CVS -0.22%)? The healthcare giant has lagged the market over the past year. Keep reading to discover whether ...

The CVS pharmacy logo is displayed on a sign above a CVS Health Corp. store in Las Vegas, Nevada on February 7, 2024.A CVS in Las Vegas has become the first location to join a new national pharmacy union, a milestone as organizers try to help thousands of U.S. pharmacy workers address what they call unsafe working conditions. Nearly 30 pharmacy staff at the Las Vegas branch of CVS's Omnicare won their union election on Thursday by a landslide margin of 87% to 13%. The pharmacists and pharmacy technicians th ...

The upcoming report from CVS Health (CVS) is expected to reveal quarterly earnings of $1.69 per share, indicating a decline of 23.2% compared to the year-ago period. Analysts forecast revenues of $89.22 billion, representing an increase of 4.6% year over year.The consensus EPS estimate for the quarter has undergone a downward revision of 0.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timef ...

CVS Health (CVS) closed the latest trading day at $67.33, indicating a -0.65% change from the previous session's end. The stock's performance was behind the S&P 500's daily loss of 0.46%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, lost 0.64%.Prior to today's trading, shares of the drugstore chain and pharmacy benefits manager had lost 14.68% over the past month. This has lagged the Retail-Wholesale sector's loss of 3.05% and the S&P 500's loss of 3.04% in that time.The upcoming earni ...